Injectable hydrogel for the regeneration of the intervertebral disc: evaluation using an ex vivo loaded disc culture model.
Lead Research Organisation:
Sheffield Hallam University
Department Name: Faculty of Health and Wellbeing
Abstract
Low back pain affects 80% of the population at some point in their lives, costing millions to the UK economy. Approximately 40% of all low back pain cases are caused by disease in the joints in the spine, known as the intervertebral discs. These discs enable the spine to move, bend and flex and act to absorb load during normal daily activities.
Intervertebral discs are similar in structure to a jam doughnut, containing a soft gel (like the jam) surrounded by a stiffer elastic ring (like the dough in the doughnut). Disease of these spinal discs which is known as disc degeneration, is the result of abnormal cell behaviour and mechanical damage, which results in an increased production of natural chemicals which can damage the disc and stimulate local nerves, making the back very painful.
Current treatments for low back pain do not target the cause of disc degeneration so they do not cure the patient, they simply treat the symptoms to make it less painful. Right now, the only successful approach surgeons use is the removal of disc material (the jam) which has squeezed out of the disc which presses nearby nerves. This surgery prevents further compression of the nerve root, making it less painful, however this is only a suitable treatment for a small proportion of sufferers where the middle of the disc has squeezed out and compresses the nerves. Most patients with low back pain without nerve compression currently have very limited treatment options. We have developed a new material (NPgel) which is a liquid outside of the body and can be injected directly into the disc via a needle without the need for major surgery. Following the injection into the disc the material becomes a gel, with similar mechanical properties to intervertebral disc tissue. In addition the material can be mixed with stem cells taken from the patient's own bone marrow, which will allow the growth of healthy new disc material in the diseased discs. The material can also be mixed with chemicals that prevent the native diseased cells of the disc from causing any further damage.
Our material has the potential to stop the disease getting worse, whilst helping the growth of new disc tissue using the stem cells we inject into the disc. We have previously tested our gel material and shown it has similar mechanical properties to intervertebral disc tissue, and does not kill human bone marrow stem cells when they are mixed together. In addition we have previously shown that cells taken from healthy people and mixed into the NPgel change their behaviour and start producing the materials from which the spinal disc is made.
Before we are allowed to perform clinical trials in humans, a series of laboratory and animal experiments are essential. We have completed initial animal safety studies showing our gel is not toxic. Here, we aim to complete mechanical tests and determine the behaviour of the gel and injected cells in a laboratory set-up which mimics the environment of the human disc. Once successful, we aim to begin studies on large animals, which is necessary before we can conduct clinical trials of our gel on people. If all this goes well, it could be used as a treatment to cure disc disease in less than 10 years.
Intervertebral discs are similar in structure to a jam doughnut, containing a soft gel (like the jam) surrounded by a stiffer elastic ring (like the dough in the doughnut). Disease of these spinal discs which is known as disc degeneration, is the result of abnormal cell behaviour and mechanical damage, which results in an increased production of natural chemicals which can damage the disc and stimulate local nerves, making the back very painful.
Current treatments for low back pain do not target the cause of disc degeneration so they do not cure the patient, they simply treat the symptoms to make it less painful. Right now, the only successful approach surgeons use is the removal of disc material (the jam) which has squeezed out of the disc which presses nearby nerves. This surgery prevents further compression of the nerve root, making it less painful, however this is only a suitable treatment for a small proportion of sufferers where the middle of the disc has squeezed out and compresses the nerves. Most patients with low back pain without nerve compression currently have very limited treatment options. We have developed a new material (NPgel) which is a liquid outside of the body and can be injected directly into the disc via a needle without the need for major surgery. Following the injection into the disc the material becomes a gel, with similar mechanical properties to intervertebral disc tissue. In addition the material can be mixed with stem cells taken from the patient's own bone marrow, which will allow the growth of healthy new disc material in the diseased discs. The material can also be mixed with chemicals that prevent the native diseased cells of the disc from causing any further damage.
Our material has the potential to stop the disease getting worse, whilst helping the growth of new disc tissue using the stem cells we inject into the disc. We have previously tested our gel material and shown it has similar mechanical properties to intervertebral disc tissue, and does not kill human bone marrow stem cells when they are mixed together. In addition we have previously shown that cells taken from healthy people and mixed into the NPgel change their behaviour and start producing the materials from which the spinal disc is made.
Before we are allowed to perform clinical trials in humans, a series of laboratory and animal experiments are essential. We have completed initial animal safety studies showing our gel is not toxic. Here, we aim to complete mechanical tests and determine the behaviour of the gel and injected cells in a laboratory set-up which mimics the environment of the human disc. Once successful, we aim to begin studies on large animals, which is necessary before we can conduct clinical trials of our gel on people. If all this goes well, it could be used as a treatment to cure disc disease in less than 10 years.
Technical Summary
The treatment of degenerative disc disease (DDD) has advanced little in the last 20 years with current treatments addressing symptoms, rather than the underlying pathology. Thus there remains a large unmet clinical need and market opportunity for effective therapies to treat DDD. The NPgel developed by our group displays temperature dependant gelation and is fully compatible with a range of cells. The properties of NPgel give it the potential for launch as a standalone therapy, in the first instance, to provide improved therapeutic options for patients through regulation as a class III device. This can be combined, if necessary, with minimally manipulated BMPCs. We have completed initial in vitro cell behaviour studies demonstrating BMPC differentiation towards NP like cells, where they produce an appropriate matrix. We have also demonstrated in vivo safety of NPgel. However, prior to full efficacy testing within a large animal model it is essential to firstly determine the behaviour of NPgel and incorporated BMPCs under mechanical loads which mimic those seen in the human IVD. The complex loading pattern seen in humans is difficult to represent within animal models. In addition it is unethical to progress to large animal efficacy studies without firstly understanding this key behaviour. Therefore, we replace animal models with post mortem human tissue for this stage of the work, in accordance with the principles of the 3Rs which are strongly supported by the MRC. This project aims to investigate the mechanical properties of the NPgel under loads which mimic those seen in the human IVD. In addition we aim to address the behaviour of minimally manipulated BMPCs incorporated within NPgel and NPgel alone following injection into IVD tissue and cultured under loads which mimic those seen in the human IVD. Understanding this behaviour will then enable progression to pre-clinical efficacy testing in a large animal model, which we anticipate will lead to clinical trials.
Planned Impact
Degenerative disc disease is one of the main causes of low back pain, which is the leading cause of disability, activity limitation and work absence throughout much of the world, imposing a high economic burden on individuals, families, communities, industry and governments. Low back pain is responsible for about one third of all work-related disability. For example, the WHO states that 149 million work days are lost each year in the USA due to lower back pain. Furthermore neck pain is also associated with disc degeneration and further impacts on disability, morbidity and economic burden. Our approach provides a number of key innovations and presents a potential paradigm shift in low back pain treatment and potentially neck pain therapy. Our strategy is the minimally invasive application of a hydrogel that can support the proliferation and differentiation of bone marrow progenitor cells thereby stimulating IVD regeneration. Upon successful completion of this project, NPgel would progress to clinical trials and a viable therapy would have a major impact on the current treatment strategies for LBP patients.
Successful development of this therapy will have a significant impact on the health and well-being of citizens in developed nations, contributing to wealth creation directly in the form of a new technology with significant commercial value and indirectly by reducing the number of work days lost through LBP. The change in emphasis, treating the cause of LBP rather than treating the symptoms, will lead to changes in organisational culture and practices in the health sector, reducing the hospitalisation time required for treatment. The IP generated during this project will be ripe for commercialisation; the European market for Minimally Invasive Spinal (MIS) devices is expected to exceed 90M Euros in 2017 (iDATA_EUSP09_RPT & iDATA_EUMIS11_RPT) and this technology could be a major contributor to this market in the future.
The economic as well as societal impacts of this work will lead to a worldwide advancement in the understanding of regenerative therapies for musculoskeletal tissues. NPgel has the potential to be a disruptive platform technology, impacting upon researchers studying regenerative strategies for a wide variety of musculosksletal tissues, indeed we have strong data supporting its use for bone regeneration.
The project is multidisciplinary in nature and this will facilitate the training of highly skilled researchers in a range of cross-disciplinary methods. Importantly the collaboration with the team in Amsterdam will provide a unique opportunity for the team from Sheffield Hallam University (SHU), to develop skills with organ culture loading systems, these skills will then be brought back to the UK where in the future such loading systems could be developed in the UK, which are not currently available which would benefit a number of UK groups. The project will impact on public acceptance and understanding of stem cells, polymer science, the ethical use of animals in research and regeneration therapies and the use of alternative model systems supporting the 3Rs principles.
Continued development and commercialisation of this material will lead to (i) a revolution in spinal regeneration therapy, (ii) the potential formation of a successful new company in the UK and (iii) a product with access to an untapped multi-billion dollar market worldwide.
Successful development of this therapy will have a significant impact on the health and well-being of citizens in developed nations, contributing to wealth creation directly in the form of a new technology with significant commercial value and indirectly by reducing the number of work days lost through LBP. The change in emphasis, treating the cause of LBP rather than treating the symptoms, will lead to changes in organisational culture and practices in the health sector, reducing the hospitalisation time required for treatment. The IP generated during this project will be ripe for commercialisation; the European market for Minimally Invasive Spinal (MIS) devices is expected to exceed 90M Euros in 2017 (iDATA_EUSP09_RPT & iDATA_EUMIS11_RPT) and this technology could be a major contributor to this market in the future.
The economic as well as societal impacts of this work will lead to a worldwide advancement in the understanding of regenerative therapies for musculoskeletal tissues. NPgel has the potential to be a disruptive platform technology, impacting upon researchers studying regenerative strategies for a wide variety of musculosksletal tissues, indeed we have strong data supporting its use for bone regeneration.
The project is multidisciplinary in nature and this will facilitate the training of highly skilled researchers in a range of cross-disciplinary methods. Importantly the collaboration with the team in Amsterdam will provide a unique opportunity for the team from Sheffield Hallam University (SHU), to develop skills with organ culture loading systems, these skills will then be brought back to the UK where in the future such loading systems could be developed in the UK, which are not currently available which would benefit a number of UK groups. The project will impact on public acceptance and understanding of stem cells, polymer science, the ethical use of animals in research and regeneration therapies and the use of alternative model systems supporting the 3Rs principles.
Continued development and commercialisation of this material will lead to (i) a revolution in spinal regeneration therapy, (ii) the potential formation of a successful new company in the UK and (iii) a product with access to an untapped multi-billion dollar market worldwide.
Publications
Baumgartner L
(2021)
Multiscale Regulation of the Intervertebral Disc: Achievements in Experimental, In Silico, and Regenerative Research
in International Journal of Molecular Sciences
Cherif H
(2024)
Injectable hydrogel induces regeneration of naturally degenerate human intervertebral discs in a loaded organ culture model
in Acta Biomaterialia
Dahia CL
(2020)
Improving reproducibility in spine research.
in JOR spine
Dahia CL
(2021)
A perspective on the ORS Spine Section initiative to develop a multi-species JOR Spine histopathology series.
in JOR spine
Rustenburg CM
(2020)
Modelling the catabolic environment of the moderately degenerated disc with a caprine ex vivo loaded disc culture system.
in European cells & materials
Schmitz TC
(2020)
Characterization of biomaterials intended for use in the nucleus pulposus of degenerated intervertebral discs.
in Acta biomaterialia
Snuggs JW
(2023)
Injectable biomaterial induces regeneration of the intervertebral disc in a caprine loaded disc culture model.
in Biomaterials science
Description | London Osteopathy Refresher course |
Geographic Reach | National |
Policy Influence Type | Influenced training of practitioners or researchers |
Impact | Training event for osteopaths which increased knowledge of causes for low back pain and possible healthcare solutions. |
Description | Versus Arthritis Advisory group |
Geographic Reach | National |
Policy Influence Type | Membership of a guideline committee |
Description | Centre for Biomaterials: Biomechanical loading capacity |
Amount | £158,135 (GBP) |
Organisation | Sheffield Hallam University |
Sector | Academic/University |
Country | United Kingdom |
Start | 01/2019 |
End | 12/2019 |
Description | Disc4All: Training network to advance integrated computational simulations in translational medicine, applied to intervertebral disc degeneration. |
Amount | € 3,996,776 (EUR) |
Organisation | European Commission H2020 |
Sector | Public |
Country | Belgium |
Start | 11/2020 |
End | 10/2024 |
Description | Grow MedTech PoF: SNIPER X |
Amount | £80,000 (GBP) |
Funding ID | SNIPER X |
Organisation | NIHR/HEFCE Higher Education Fund for England |
Sector | Public |
Country | United Kingdom |
Start | 02/2020 |
End | 01/2021 |
Description | Grow MedTech PoF: SNIPER: Injectable Spinal Fusion |
Amount | £20,000 (GBP) |
Organisation | NIHR/HEFCE Higher Education Fund for England |
Sector | Public |
Country | United Kingdom |
Start | 08/2019 |
End | 01/2020 |
Description | Strategic investment board funding - Sheffield Hallam University |
Amount | £50,000 (GBP) |
Organisation | Sheffield Hallam University |
Sector | Academic/University |
Country | United Kingdom |
Start | 11/2017 |
End | 04/2018 |
Description | iPSpine |
Amount | € 15,396,030 (EUR) |
Funding ID | 825925 |
Organisation | European Commission H2020 |
Sector | Public |
Country | Belgium |
Start | 01/2019 |
End | 12/2024 |
Title | Goat degeneration loading model |
Description | Loaded culture system for whole intervertebral discs where controlled degeneration can be induced which mimics disc degeneration seen in humans. (note publication under review) |
Type Of Material | Model of mechanisms or symptoms - in vitro |
Year Produced | 2019 |
Provided To Others? | No |
Impact | This model can be used for testing new therapies. |
Description | Amsterdam |
Organisation | VU University Medical Center |
Country | Netherlands |
Sector | Academic/University |
PI Contribution | Knowledge on intervertebral disc degeneration and pathogenesis. Novel therapies for new treatments |
Collaborator Contribution | Loading environment and culture systems for modelling intervertebral disc |
Impact | none yet |
Start Year | 2017 |
Description | Montreal Loaded Disc Culture System |
Organisation | McGill University |
Department | Montreal Children's Hospital Research Institute |
Country | Canada |
Sector | Academic/University |
PI Contribution | Collaboration on human loaded disc culture system, and development of organ system for testing materials in human IVDs. Contribution of knowledge of Human disc degenration, culture systems and mimiking in vivo environment. Testing of new materials. |
Collaborator Contribution | Loaded disc culture system, and personnel working on collaborative project. |
Impact | None yet |
Start Year | 2019 |
Title | Composite hydrogel |
Description | A method of producing a nanocomposite hydrogel comprises mixing an aqueous composition of water soluble monomer, clay particles and free-radical polymerization initiator, characterized in that i) the polymerization is carried out above the gelation temperature of the resulting polymer and subsequently cooling the polymer to cause gelation, and characterized in that the initiator is selected such that it only dissociates into radicals at a temperature higher than the gelation temperature of the resulting polymer. The gel is formed with clay particles cross-linking the polymer. In preferred embodiments the monomer is N-isopropyl acrylamide. The method provides the advantage that the polymer can be formed and kept in an ungelled state. The hydrogel can be used in the medical field by forming the polymer above the gelation temperature and injecting the ungelled polymer into e.g. a spinal disk, then allowing to cool to form the gel in situ. |
IP Reference | GB2493933 |
Protection | Patent / Patent application |
Year Protection Granted | 2013 |
Licensed | Yes |
Impact | Specific use of patent for licencing application, work from grant supported this licencing oppotunity |
Description | 3D DTA training course |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Postgraduate students |
Results and Impact | Workshop for PhD students from doctoral training alliance on 3D cell culture, lead to other collaborations and supporting students around the country |
Year(s) Of Engagement Activity | 2019 |
Description | Back Pain Patient User Group |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | patient user group meeting for patients with LBP, current research avenues within the group discussed and patients shared their lived experiences |
Year(s) Of Engagement Activity | 2020 |
Description | Bio engineering event |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Professional Practitioners |
Results and Impact | presentation and lab tour - number individuals contacted after saying had opened minds and asked for other info |
Year(s) Of Engagement Activity | 2019 |
Description | Cafe Sceintific - Scunthorpe |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Public/other audiences |
Results and Impact | Café scientific presentation discussing the research and the reasons for low back pain. |
Year(s) Of Engagement Activity | 2019 |
Description | Explore event - 2019 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Public/other audiences |
Results and Impact | explore event in Sheffield, aimed principally at children but wide audience, lots of follow up contacts and questions. |
Year(s) Of Engagement Activity | 2019 |
Description | Explore event sheffield |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Public/other audiences |
Results and Impact | Presented within the Sheffield Explore event discussing the research funded by the MRC and sparked lots of interest into what research is undertaken. |
Year(s) Of Engagement Activity | 2018 |
Description | Manchester SciBar |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Public/other audiences |
Results and Impact | Science bar public presentation about the research undertaken explaining the causes and possible treatments for LBP |
Year(s) Of Engagement Activity | 2018 |
Description | PPI ask the researcher event |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | PPI group presentation on research, also lead to number of patients joining local patient user group |
Year(s) Of Engagement Activity | 2019 |
Description | Patient group Workshop |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | Patient User group meeting discussion of need for new therapies for low back pain and discussing current research plans |
Year(s) Of Engagement Activity | 2019 |
Description | Presentation pitch at BIotrinity Event |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Industry/Business |
Results and Impact | Pitch presented at Bio trinity event April 2020 resulting in engagment with a number of potential industrial partners and manufacturing partners. |
Year(s) Of Engagement Activity | 2020 |
URL | https://www.obn.org.uk/Events-Calendar/283/biotrinity-2020-28-apr-2020 |
Description | School lab session |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Schools |
Results and Impact | 30 students attended STEM lab activity on cells and gels for low back pain which disseminated research, raised awareness of the need for new treatments and sparked interest into research |
Year(s) Of Engagement Activity | 2018 |
Description | Schools session Cell and Gels for low back pain |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Schools |
Results and Impact | Schools visit during science week which increased interest in school children about science and research and increased understanding about back pain. |
Year(s) Of Engagement Activity | 2018 |
Description | Science week 2019 school session |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Schools |
Results and Impact | In School session during science week, sparked questions and discussion afterwards, raised awareness of research and stem cells. |
Year(s) Of Engagement Activity | 2019 |
Description | Science week TED style talk |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Public/other audiences |
Results and Impact | Public presentation to wide audience, lots of interest from the audience and a clinician in the audience is interested in alternative uses for the hydrogel |
Year(s) Of Engagement Activity | 2019 |
Description | Unmet needs workshop - Leeds |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Professional Practitioners |
Results and Impact | Workshop identifying unmet needs - contribution lead to strategy development. |
Year(s) Of Engagement Activity | 2019 |
Description | Versus arthritis user group |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | patient user group meeting - discussed research areas and patient input, very engaged audience with lots of questions. |
Year(s) Of Engagement Activity | 2020 |